Twitter Facebook LinkedIn YouTube

Hemostemix is hiring 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal, Following MUHC Foundation Funding and Applying for Grants to Fund Up to 75% of 5-Year Expenses

Video Platform Video Management Video Solutions Video Player

Hemostemix (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is hiring 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal, Following MUHC Foundation Funding and Applying for Grants to Fund Up to 75% of 5-Year Expenses. This staffing requirement arose because of the recently announced $250,000 Letter of Commitment for funding from the McGill University Health Centre Foundation to fund $250,000 of clinical trial expenses of a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.

Additional Information:

Company: Hemostemix Inc
Website: www.hemostemix.com
Stock Symbol: TSXV:HEM
Date Published: Jan 23, 2023
Transcript: Available

Video Transcript:

Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) (new symbol), an autologous stem cell therapy company, is hiring four biotechnologists to re-establish the company’s production of ACP-01 in Montreal.

This staffing requirement arose because of the recently announced $250,000 Letter of Commitment for funding from the McGill University Health Centre Foundation to fund $250,000 of clinical trial expenses of a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.

This funding is a result of the 2020 launch of the Foundation’s $200 million Dream Big Campaign to change the course of lives and medicine.

The company is hiring an experienced stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists.

Coincidentally, Hemostemix has applied for Federal and Provincial grant funding that may cover up to 75% of its capital and operating expenses to build and operate its cGMP facility during its first five years of operation.

Thomas Smeenk, CEO, has joined us today to discuss this news.

Welcome Thomas, it looks like things are moving pretty quickly following the McGill funding.

.…pause….thank you Thomas

Founded in 2003, Hemostemix’ principal business is to develop, manufacture and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments.

A winner of the World Economic Forum Technology Pioneer Award, the company is commercializing its lead product ACP-01, an autologous angiogenic cell precursor for cardiomyopathy and other diseases of ischemia.

The company’s process for harvesting stem cells is less invasive, as the stem cells are taken from a patient’s blood, which is a simplified process as compared to taking stem cells from fatty tissue or bone marrow.

The shares are currently trading at $0.25.

For more information, please visit the company’s website at www.hemostemix.com, contact Thomas Smeenk, President, CEO and Co-Founder at 905-580-4170 or by email at TSmeenk@hemostemix.com.